Saroglitazar is a novel drug developed in India for the treatment of diabetic dyslipidemia and Non-Alcoholic Fatty Liver Disease (NAFLD)
10.3892/or.2016.4599 Oncol
Quick Answer: GLP-1 affects multiple brain regions including the hypothalamus, brainstem, mesolimbic reward system, hippocampus, and cortical areas involved in appetite regulation, reward processing, and cognitive function
GLP-1 stimulates insulin secretion, inhibits glucagon secretion, slows gastric emptying, and promotes satiety, all of which contribute to weight loss
Call 999 or go to A&E if you're at immediate risk, contact your GP immediately, call NHS 111, or contact the Samaritans on 116 123 for 24/7 support